Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2019-10-23 Regulatory Filings
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Polyphor and the University of Zurich announces publication in 'Nature' of the unique mechanism of action of a new class of antibiotics.
Regulatory Filings Classification · 100% confidence The document is a short news release dated October 23, 2019, announcing the publication of research findings regarding a new class of antibiotics in the journal 'Nature'. It details scientific discoveries, mentions academic and industrial partners, and provides contact information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a general announcement about scientific progress and collaboration that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general regulatory announcement/news category, which is RNS (Regulatory Filings). Given the short length and the nature of the announcement (news details), RNS is the most appropriate fallback.
2019-10-23 English
Polyphor to present at the H.C. Wainwright Global Investment Conference
Report Publication Announcement Classification · 99% confidence The document is a short news release dated September 4, 2019, announcing that Polyphor AG will present at the H.C. Wainwright Global Investment Conference. It provides details about the presentation date, time, location, and includes a link to a webcast. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing detailing transactions or results. It is an announcement about an upcoming investor event where the company will present its pipeline and overview. This aligns best with an Investor Presentation (IP) announcement, or more generally, a corporate event announcement. Since the document itself is an announcement about presenting information to investors, and it is very short (3891 chars), it fits the pattern of an announcement rather than the presentation itself. However, the content is specifically about an upcoming presentation to investors. Given the options, 'Investor Presentation (IP)' is the most relevant category for the *topic*, but since this is an announcement *about* the presentation, and not the presentation slides themselves, it could also be considered a general Regulatory Filing (RNS) or Report Publication Announcement (RPA) if the presentation slides were expected to follow. Since the core subject is the presentation itself, and it's a corporate update, I will classify it as an Investor Presentation (IP) as it directly relates to investor outreach regarding company strategy/pipeline, even though it's the announcement of the event rather than the presentation material itself. If the document were longer and contained the actual presentation slides, IP would be certain. Given the context of corporate news releases about investor events, IP is the closest fit for the subject matter.
2019-09-04 English
Polyphor announces financial results for the first half 2019 and realigns strategy
Earnings Release Classification · 100% confidence The document explicitly states it 'publishes today its financial results for the first half of 2019' and includes detailed financial highlights (Profit and Loss, Balance Sheet) for the period ending 30.6.2019. The title mentions 'financial results for the first half 2019'. This content strongly indicates a comprehensive report covering a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it is presented as an ad-hoc announcement, the core content is the financial report itself, not just an announcement of its publication (which would be RPA/RNS). Since it covers the first half (H1), IR is more specific than the general ER (Earnings Release, usually quarterly highlights). H1 2019
2019-09-04 English
Polyphor to host a Key Opinion Leader Meeting in New York on novel approach-es to the treatment of metastatic breast cancer
Regulatory Filings Classification · 100% confidence The document is a news release from Polyphor AG, dated August 20, 2019, announcing that they will host a Key Opinion Leader (KOL) breakfast meeting in New York regarding metastatic breast cancer treatment and their compound Balixafortide. This announcement pertains to an upcoming corporate event involving key medical experts and investors, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is an announcement about an investor/medical relations event, which does not fit neatly into the primary financial filing categories. Since it is a specific corporate announcement that doesn't match AGM-R (which is for materials *from* the AGM), ER, CT, or IP (which is usually a detailed presentation deck), the most appropriate general category for corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), as it is disseminated via a news service (EQS Group-News) and contains general corporate updates.
2019-08-20 English
Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on July 17, 2019, pursuant to Art. 53 KR (likely referring to Swiss regulatory rules). It discusses the closure of Phase III clinical studies (PRISM studies) for a drug (murepavadin) due to safety findings (acute kidney injury) and outlines future evaluation plans. It also mentions an update will be given with the 'half year results' and schedules an immediate conference call for investors. This type of immediate, material, non-periodic disclosure regarding clinical trial status and future plans, often mandated by stock exchange rules for listed companies, fits best under the general 'Regulatory Filings' category (RNS) as it is not a formal financial report (10-K, IR, ER) nor a specific management/governance document. It is an immediate regulatory disclosure.
2019-07-17 English
Polyphor appoints Frank Weber as new Chief Medical and Development Officer
Board/Management Information Classification · 100% confidence The document is titled 'News Details' and is released as an 'Ad-hoc' announcement on June 27, 2019. The core content announces the appointment of a new Chief Medical and Development Officer (CMDO), Frank Weber, and details his transition from the Board of Directors. This type of announcement, concerning changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'.
2019-06-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.